ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Novel antimicrobial and antiangiogenic properties from riparin-type benzamides: synthesis, biological evaluation, and docking analysis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global increase in antimicrobial resistance, along with the role of pathological angiogenesis in infection-associated inflammation, underscores the need for multifunctional therapeutic agents. In this study, a series of riparin-type benzamides were synthesized using efficient and accessible synthetic methods, yielding structurally diverse compounds, and their antimicrobial and antiangiogenic potential was evaluated. Among these, riparin III (3c) exhibited the most potent and broad-spectrum antimicrobial activity, effectively inhibiting Gram-positive and Gram-negative bacterial strains as well as Candida spp. Furthermore, riparin I (3a), riparin II (3b), and riparin III (3c) exhibited antiangiogenic activity, suggesting their potential therapeutic relevance in infection-associated inflammation. Toxicity assessments indicated low cytotoxicity at the effective concentrations, supporting the safety profile of the compounds. Molecular docking analysis corroborated the in vitro findings, revealing strong interactions between riparin I (3a) and fungal cell wall targets, as well as between riparin III (3c) and key bacterial enzymes involved in resistance and replication. Overall, these results highlight riparin I (3a), riparin II (3b), and riparin III (3c) as promising multifunctional candidates for the development of antimicrobial agents capable of addressing the current challenges in infection control, including antimicrobial resistance and inflammation-associated pathologies.
Indexed as
Identifiers
41247454What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.